Loading patent…
AssigneeiTeos Belgium SA
InventorsMarcel de Matas, Paul Dickinson, Manfred Schneider, Sally Ross, Esha Gangolli, Shouraydeep Srivastava, Joanne Lager, Edwin Aret, Chantalle Van Berkel, Pratheepan Madasamy, Chiara Martinoli, Maura Rossetti
Estimating the term…
A hydrochloride salt of inupadenant, pharmaceutical compositions thereof, methods of making pharmaceutical compositions of a hydrochloride salt of inupadenant (e.g., crystalline hydrochloride salt of inupadenant) and methods of using the pharmaceutical compositions in combination with carboplatin and pemetrexed in the treatment of non-small cell lung cancer (NSCLC), including squamous NSCLC and nonsquamous NSCLC.
Amorphous inupadenant hydrochloride.
2-9. (canceled)
Crystalline inupadenant hydrochloride.
Form 2 inupadenant hydrochloride.
Inupadenant hydrochloride hydrate.
14-15. (canceled)
18-60. (canceled)
A pharmaceutical composition comprising:
64-183. (canceled)
A process for manufacturing a capsule pharmaceutical composition comprising the steps of:
A method for treating a cancer in a patient in need thereof, the method comprising administering to the patient a pharmaceutical composition comprising crystalline inupadenant hydrochloride and at least one pharmaceutically acceptable excipient.
186-193. (canceled)
A method for treating non-small cell lung cancer (NSCLC) in a patient in need thereof, the method comprising administering to the patient the pharmaceutical composition comprising crystalline inupadenant hydrochloride and at least one pharmaceutically acceptable excipient, in combination with pemetrexed and carboplatin.
195-229. (canceled)
Form 1 inupadenant hydrochloride.
(canceled)
Milled inupadenant hydrochloride.
248-254. (canceled)
Dependencies are inferred from the claim text.